Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5458 USD | -3.48% | -16.07% | +6.44% |
05-09 | Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M | MT |
04-01 | Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.44% | 68.1M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- ATRA Stock
- News Atara Biotherapeutics, Inc.
- Atara Says ATA3219 IND Application Approved by FDA for Lupus Nephritis CAR T-Cell Therapy